| Literature DB >> 25343021 |
Seog-Jin Seo1, Chinmaya Mahapatra1, Rajendra K Singh1, Jonathan C Knowles2, Hae-Won Kim3.
Abstract
Interest in osteochondral repair has been increasing with the growing number of sports-related injuries, accident traumas, and congenital diseases and disorders. Although therapeutic interventions are entering an advanced stage, current surgical procedures are still in their infancy. Unlike other tissues, the osteochondral zone shows a high level of gradient and interfacial tissue organization between bone and cartilage, and thus has unique characteristics related to the ability to resist mechanical compression and restoration. Among the possible therapies, tissue engineering of osteochondral tissues has shown considerable promise where multiple approaches of utilizing cells, scaffolds, and signaling molecules have been pursued. This review focuses particularly on the importance of scaffold design and its role in the success of osteochondral tissue engineering. Biphasic and gradient composition with proper pore configurations are the basic design consideration for scaffolds. Surface modification is an essential technique to improve the scaffold function associated with cell regulation or delivery of signaling molecules. The use of functional scaffolds with a controllable delivery strategy of multiple signaling molecules is also considered a promising therapeutic approach. In this review, we updated the recent advances in scaffolding approaches for osteochondral tissue engineering.Entities:
Keywords: Osteochondral repair; interfacial tissue; scaffold design; therapeutic functions; tissue engineering
Year: 2014 PMID: 25343021 PMCID: PMC4206689 DOI: 10.1177/2041731414541850
Source DB: PubMed Journal: J Tissue Eng ISSN: 2041-7314 Impact factor: 7.813
Figure 1.Cross section of osteochondral tissue.
Current surgical techniques for osteochondral repair.
| Surgical procedure | Invasive degree | Features | Reference |
|---|---|---|---|
| Mosaic-type osteochondral autologous transplantation (OAT) and microfracture (MF) | HIGH | Patient clinical improvement in OTA and MF | Gudas et al.[ |
| MF-combined osteochondral paste | MODERATE | Poor Safranin-O and type II collagen staining in MF group | Xing et al.[ |
| MF with hole geometry | HIGH | No significant effect in osteochondral repair | Kok et al.[ |
| Mix-mosaicplasty | VERY HIGH | Fibrocartilage-like tissue | Leng et al.[ |
| Mosaicplasty grafting | MODERATE | Improved mean pain score | Solheim et al.[ |
| ACI | HIGH | Hypertrophy of transplant | Niemeyer et al.[ |
| MODERATE | Effective in younger patients | Ossendorf et al.[ | |
| MACI | MODERATE | Limited effective over 24 months | Basad et al.[ |
| Arthroscopic autogeneous osteochondral mosaicplasty | HIGH | Multiple surgery procedure | Hangody et al.[ |
| Total joint replacement | VERY HIGH | Metal toxicity and sensitivity | Evans et al.[ |
ACI: autologous chondrocyte implantation; MACI: matrix-induced autologous chondrocyte implantation; GAG: glycosaminoglycan.
Cell resources currently used in osteochondral tissue engineering.
| Cell resource | Cell type | Features | Reference |
|---|---|---|---|
| Stem cells | Umbilical cord MSCs | Facilitate scaffold and tissue integration. | Wang et al.[ |
| Amniotic fluid–derived stem cells | Differentiation into osteoblasts and chondrocytes encapsulated in 2% of alginate | Rodrigues et al.[ | |
| Synovium-derived MSCs | Characteristics of MSCs with an ability to differentiate into osteoblasts and chondrocytes. | Koga et al.[ | |
| Bone marrow-derived MSCs | Development toward both chondro- or osteo-lineages without fibrous tissue formation | Betsch et al.[ | |
| Tissue-specific cells | Chondrocytes | Complete mechanical stability | Horas et al.[ |
| Osteoblasts | High SPP1 mRNA expression | Innes et al.[ | |
MSCs: mesenchymal stem cells; ECM: extracellular matrix; RUNX2: Runt-related transcription factor 2.
Figure 2.Schematic illustration of cell–cell contact and cell–matrix contact in the cell-laden biphasic scaffold resulting from the strategy used to stabilize the mechanical property and to integrate the interfaces of each phase.
Growth factors currently used in osteochondral tissue engineering.
| Signaling molecule | Carrier | Observations | Reference | |
|---|---|---|---|---|
| Gene | BMP-2 | Porous PLGA | Increased GAG content in treated groups | Chen et al.[ |
| Collagen sponge reinforced by PEG | Increased ALP activity in test groups | Hosseinkhani et al.[ | ||
| VEGF/BMP-2 | Hollow cylindrical PLGA scaffold | Regeneration proximal and distal ends of the bony defects by co-expression | Lin et al.[ | |
| hIGF-I gene–modified BMSCs | 1.2 wt/% calcium-alginate solution | hIGF-I gene effective expression with high subchondral bone and cartilage integration | Leng et al.[ | |
| Growth factor | TGFβ-1/BMP-2 | PLGA microspheres, dispersed in an alginate matrix | High gene expression in the treated groups | Reyes et al.[ |
| TGF-β3/IGF-I | Gelatin microspheres in oligo-PEG fumarate hydrogel | Excellent formation of subchondral bone and GAG | Yi et al.[ | |
| BMP-2 | Hyaluronic hydrogel system | Healing with fibrocartilage-like tissue formation. | Aulin et al.[ | |
BMP: bone morphogenetic protein; GAG: glycosaminoglycan; ALP: alkaline phosphatase; PLGA: polylactide-co-glycolide; VEGF: vascular endothelial growth factor; PEG: polyethylene glycol; BMSCs: bone marrow mesenchymal stem cells; ECM: extracellular matrix; hIGF-I: human insulin-like growth factor I; TGF: transforming growth factor.
Potential delivery of therapeutic molecules including growth factors, drugs, or genes from the scaffold for osteochondral repair.
| Growth factor | Osteochondral effects | Reference |
|---|---|---|
| TGF-β1 | Synchronized development of cartilage and subchondral bone. | Scherer et al.[ |
| FGF-2 | Hyaline-like cartilage and subchondral bone. | Maehara et al.[ |
| BMP-2 | High-quality cartilage and tissue integration. | Noel et al.[ |
| BMP-7 | Formation of mineralized tissue and ectopic bone. | Dormer et al.[ |
| IGF-I | Superior growth morphology and surface architecture of the neotissue. | Wang et al.[ |
| VEGF | Critical factor for chondrocytes survival. | Sakata et al.[ |
BMP: bone morphogenetic protein; VEGF: vascular endothelial growth factor; PEG: polyethylene glycol; IGF-I: insulin-like growth factor I; TGF: transforming growth factor; FGF: fibroblast growth factor.
Figure 3.Spatiotemporal delivery from a biphasic scaffold containing therapeutic molecule–loaded microspheres with different degradation rates.[98,99]